MedTrace Logo

Efficacy of Rivastigmine in Patients With Down Syndrome

NCT00748007 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2012-11-28

No results posted yet for this study

Summary

This study is to understand the efficacy on language and cognitive function in Down syndrome patients who take Rivastigmine.

Conditions

  • Down Syndrome

Interventions

DRUG

Rivastigmine

Exelon (1.5mg/cap) 1.5 mg bid

Sponsors & Collaborators

  • National Taiwan University Hospital

    lead OTHER

Principal Investigators

  • Wuh-Liang Hwu, MD. PhD · National Taiwan University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
8 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00748007 on ClinicalTrials.gov